![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Tobevibart (VIR-3434), a Monoclonal Antibody, Resistance Analysis in Participants With Chronic HBV: Results From a Phase 1, Single-dose Study
|
|
|
European Association for the Study of the Liver (EASL™) Congress; 5-8 June 2024; Milan, Italy.
Hasan Imam,1 Julia di Iulio,1 Thanh Quach,1 Yi-Pei Chen,1 Carley E. McAlister,1 Sonia Maciejewski,1 Keith Boundy,1 Andre Arizpe,1 Kosh Agarwal,2 Man-Fung Yuen,3 Andrea Cathcart,1 Gregory Camus1
1Vir Biotechnology, Inc, San Francisco, CA, USA; 2King's College Hospital, London, UK; 3Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, Hong Kong.
![0613241](../images/061424/061424-3/0613241.gif)
![0613242](../images/061424/061424-3/0613242.gif)
![0613243](../images/061424/061424-3/0613243.gif)
![0613244](../images/061424/061424-3/0613244.gif)
![0613245](../images/061424/061424-3/0613245.gif)
![0613246](../images/061424/061424-3/0613246.gif)
![0613247](../images/061424/061424-3/0613247.gif)
![0613248](../images/061424/061424-3/0613248.gif)
![0613249](../images/061424/061424-3/0613249.gif)
![06132410](../images/061424/061424-3/06132410.gif)
![06132411](../images/061424/061424-3/06132411.gif)
![06132412](../images/061424/061424-3/06132412.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|